Viatris Inc VTRS
News
Viatris to Participate in the BofA Securities 2024 Health Care Conference
Viatris Expands Its Wellbeing Program With the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
Thinking about buying stock in Mirum Pharmaceuticals, Entera Bio, Andean Precious Metals, Viatris, or Biomx?
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
Charts turn bullish on health-care stocks as sector takes early lead in 2024
Viatris makes progress on Ozempic patent challenge
Challenge to Novo Nordisk Obesity Drug Patents Rejected in US
Ocuphire Shares Rally Premarket as FDA Approves Ryzumvi Eye Drops
Viatris and Ocuphire Pharma get FDA green light for eye treatment